
About Neoprospecta
Neoprospecta is a Healthcare company based in Florianopolis (Brazil) founded in 2010. Microbiome analysis and monitoring via NGS and bioinformatics are offered. Neoprospecta has raised $1.78 million across 1 funding round from investors including CVentures. Neoprospecta offers products and services including Diagnóstico Microbiológico Digital, Plataforma Neobiome, and Sequenciamento de Genomas. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery.
Company details
Neoprospecta was founded in 2010 in Florianópolis, Brazil, focusing on microbial analysis in the biotechnology sector. Services encompass next-generation sequencing on the Illumina platform, bespoke bioinformatics, and qPCR for applications including infectious disease surveillance, antibiotic resistance monitoring, and contamination tracking in food, hospitals, and animal health. Digital Microbiological Diagnosis tools, such as DMD Microbiome for fungi, bacteria, and protozoa identification, and DMD Resistoma for resistance gene detection, are provided.
- Total Equity Funding$1.78M (USD)
in 1 rounds
- Latest Funding Round$1.78M (USD), Seed
Sep 2014
- Investors
Products & Services of Neoprospecta
Neoprospecta offers a comprehensive portfolio of products and services, including Diagnóstico Microbiológico Digital, Plataforma Neobiome, and Sequenciamento de Genomas.
Identifies microorganisms using genetic markers and DNA sequencing.
Manages and analyzes microbial data for quality control applications.
Performs genome and transcriptome sequencing for research and diagnostics.
Apps and channels of Neoprospecta
its YouTube channel Neoprospecta Microbiome Technologies has 1.06K subscribers and 30 videos.
Videos from Neoprospecta
The most watched videos on Neoprospecta's YouTube channel, Neoprospecta Microbiome Technologies (1.06K subscribers). Click a video to play it here.
More on Neoprospecta Microbiome Technologies.
Funding Insights of Neoprospecta
Neoprospecta has successfully raised a total of $1.78M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.78 million completed in September 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.78M
- Total Rounds 1
- Last Round Seed — $1.78M
- First Round $1.78M
(Sep 2014)
- Investors Count 1
All 1 funding rounds of Neoprospecta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2014 | $1.78M | Seed | – | CVentures | – |
1 investors in total: 1 institutional.
Investors in Neoprospecta
Neoprospecta has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include CVentures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| cventureseg.com |
Investor details for Neoprospecta
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Neoprospecta
2 dated milestones of Neoprospecta across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Neoprospecta is founded.
- Funding First funding round of $1.8M.
Web traffic of Neoprospecta
The website of Neoprospecta (neoprospecta.com) receives about 7.9K visits a month.
- Monthly visits7.9K
▼ 8.7% vs previous month
Websites whose visitors overlap most with Neoprospecta. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biocant.pt | 100% | 1.9K | #7,429,645 | View details | |
lifesci.dundee.ac.uk | lifesci.dundee.ac.uk | 92% | – | ||
| masslifesciences.com | 91% | #828,340 | View details | ||
ifsudestemg.edu.br | ifsudestemg.edu.br | 58% | #86,363 | – | |
science.uwe.ac.uk | science.uwe.ac.uk | 57% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Neoprospecta
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Neoprospecta
Neoprospecta was founded in 2010 and raised its 1st funding round 4 years after it was founded.
Neoprospecta is headquartered in Florianopolis, Brazil. It is registered at Florianopolis, Santa Catarina, Brazil.
Neoprospecta is a funded company, having raised a total of $1.78M across 1 funding round to date. The company's 1st funding round was a Seed of $1.78M, raised on Sep 2014.
Neoprospecta was founded in 2010 in Florianópolis, Brazil, focusing on microbial analysis in the biotechnology sector. Services encompass next-generation sequencing on the Illumina platform, bespoke bioinformatics, and qPCR for applications including infectious disease surveillance, antibiotic resistance monitoring, and contamination tracking in food, hospitals, and animal health. Digital Microbiological Diagnosis tools, such as DMD Microbiome for fungi, bacteria, and protozoa identification, and DMD Resistoma for resistance gene detection, are provided.
Neoprospecta offers Diagnóstico Microbiológico Digital, Plataforma Neobiome, and Sequenciamento de Genomas.
Neoprospecta has 1 investor. Key investors include CVentures.